{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 56,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 156,
  "notes": "The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/5",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "* Post-Osimertinib resistant population shown for EGFRm NSCLC except for SCLC transformation ** Co-occurring activating MAPK pathway alterations exclude EGFR overexpression Source: SEER database (2020), ECIS database (2020), GLOBOCAN database (2020), The AACR Project GENIE Consortium version 8.1 (2020), TCGA Research Network: https://www.cancer.gov/tcga, Tyner JW et al. (2018) PMID: 30333627, Brenner CW et al (2013) PMID: 24120142, Chen J et al. (2020) PMID: 32015526, and Ostrom QT, et al. (2020) PMID: 33123732",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40e24e58-a70c-4303-823e-3aa5198822ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.28,
        "x": 0.36,
        "y": 0.835
      },
      "kind": "legend",
      "text": "Blue ocean opportunities (teal) and Red ocean opportunities (red)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "668a1c14-5d51-45ae-b126-478cb0b7beaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "table",
      "text": "Table of cancer alterations by type and region",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2f33224-f139-4dd8-b12c-dd52345d3deb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "~5.5m lives at stake annually worldwide with RAS/MAPK pathway alterations; 70+% of unmet needs are “blue oceans” with no approved targeted therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39d7168b-9163-47a2-8a34-f1190fc41bbb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Blue Ocean Strategy",
      "slug": null,
      "matchId": "2c63e00d-facf-4480-be64-060fbb18e739",
      "evidence": "Explicit use of 'blue ocean' vs 'red ocean' terminology to categorize market opportunities.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}